Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.59 |
| ▸ | RRM1 | P23921 | 1/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506841 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL17817201 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL15662048 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL671932 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL15662046 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL23001174 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL506842 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL6419557 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL21367553 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 | |
| SCHEMBL248428 | 0.91 | DPP7 (0.71) | DPP7RRM1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662842-B2 | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents | Ohio State Univesity Research Foundation (US) | 2010-02-16 | — | — | US | disclosed |
| US-20070155807-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155807-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | SRM, SAT1, SMS | DPP7 622/4885RRM1 2505/4885GNAI3 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.